Preclinical evaluation of an inhibitor of cytosolic phospholipase A 2α for the treatment of asthma

Journal of Pharmacology and Experimental Therapeutics

Volumn 340, Issue 3, 2012, Pages 656-665

  Hewson, Christopher A ^a   Patel, Sheena ^a   Calzetta, Luigino ^b,e   Campwala, Hinnah ^a   Havard, Suzanne ^c   Luscombe, Emma ^a   Clarke, Philip A ^a   Peachell, Peter T ^c   Matera, Maria G ^d   Cazzola, Mario ^b   Page, Clive ^e   Abraham, William M ^f   Williams, Cara M ^g   Clark, James D ^g   Liu, Wai L ^a   Clarke, Nicholas P ^a   Yeadon, Michael ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f MOUNT SINAI MEDICAL CENTER   (United States)

^g PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; CYTOSOLIC PHOSPHOLIPASE A2; CYTOSOLIC PHOSPHOLIPASE A2 ALPHA; IMMUNOGLOBULIN E ANTIBODY; IONOMYCIN; LEUKOTRIENE B4; PEPTIDOLEUKOTRIENE; PF 5212372; PROSTAGLANDIN D2; PROSTAGLANDIN E2; THROMBOXANE A2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHOSPASM; CELL POPULATION; CELL STIMULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ALVEOLUS CELL; MALE; MAST CELL; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; SHEEP; SINGLE DRUG DOSE;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ASTHMA; BRONCHOCONSTRICTION; CALCIUM IONOPHORES; CELL LINE; CYTOSOL; ENZYME INHIBITORS; GROUP IV PHOSPHOLIPASES A2; HUMANS; MAST CELLS; PHENYLPROPIONATES; PROSTAGLANDIN D2; SHEEP; SULFONAMIDES;

EID: 84863150795     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.186379     Document Type: Article

References (37)

1. Abraham WM (2008) Modeling of asthma, COPD and cystic fibrosis in sheep. Pulm Pharmacol Ther 21:743-754.
2. Ali H and Pearce FL (1985) Isolation and properties of cardiac and other mast cells from the rat and guinea-pig. Agents Actions 16:138-140. (Pubitemid 15116676)
3. Baptist AP and Reddy RC (2009) Inhaled corticosteroids for asthma: are they all the same? J Clin Pharm Ther 34:1-12.
4. Barnes NB, Pavord IP, Churchalin AC, Bell JB, Hunter MH, Payton MP, Pearce Collins LPC, Pettipher RP, Steiner JS, and Perkins MP (2009) A randomised, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 on moderate persistent asthma. Presented at the European Respiratory Society Annual Congress; 2009 Sep 12-16; Vienna, Austria, European Respiratory Society, Lausanne, Switzerland.
5. 2 stimulation. Exp Cell Res 222:379-384.
6. Björck T, Gustafsson LE, and Dahlén SE (1992) Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. Am Rev Respir Dis 145:1087-1091.
7. Boyce JA (2008) Eicosanoids in asthma, allergic inflammation, and host defense. Curr Mol Med 8:335-349.
8. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092-1102. (Pubitemid 40365350)
9. Brightling CE, Bradding P, Pavord ID, and Wardlaw AJ (2003) New insights into the role of the mast cell in asthma. Clin Exp Allergy 33:550-556. (Pubitemid 36629677)
10. Calzetta L, Spina D, Cazzola M, Page CP, Facciolo F, Rendina EA, and Matera MG (2011) Pharmacological characterization of adenosine receptors on isolated human bronchi. Am J Respir Cell Mol Biol 45:1222-1231.
11. 2- Adrenoceptor agonists: current and future direction. Br J Pharmacol 163:4-17.
12. Drazen JM, Israel E, and O'Byrne PM (1999) Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 340:197-206. (Pubitemid 29063217)
13. Fujimura M, Sasaki F, Nakatsumi Y, Takahashi Y, Hifumi S, Taga K, Mifune J, Tanaka T, and Matsuda T (1986) Effects of a thromboxane synthetase inhibitor (OKY-046) and a lipoxygenase inhibitor (AA-861) on bronchial responsiveness to acetylcholine in asthmatic subjects. Thorax 41:955-959. (Pubitemid 17213107)
14. 2 potentiates airway responsiveness to histamine and methacholine. Am Rev Respir Dis 133:252-254.
15. 2 family. Prog Lipid Res 45:487-510.
16. Global Initiative for Asthma (2002) Global Strategy for Asthma Management and Prevention, NIH Publication 02-3659, National Institutes of Health, Bethesda.
17. Goldstein JL, Jungwirthová A, David J, Spindel E, Bouchner L, Pešek F, Searle S, Škopek J, Grim J, Ulc&caron I, et al. (2010) Clinical trial: endoscopic evaluation of naproxen etemesil, a naproxen prodrug, vs. naproxen: a proof-of-concept, randomized, double-blind, active-comparator study. Aliment Pharmacol Ther 32:1091-1101.
18. 2 in respiratory allergy. Biochimie 92:588-593.
19. 2-induced bronchoconstriction is mediated only in part by the thromboxane prostanoid receptor. Eur Respir J 8:411-415.
20. Mathison DA and Koziol JA (2002) Marginal utility of montelukast for persistent asthma. Chest 121:334-337. (Pubitemid 34132966)
21. 2α: hit to lead optimization. J Med Chem 49:135-158.
22. 2α inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl) -1-(diphenylmethyl)-1H-indol-3-yl] propyl}benzoic acid, efipladib. J Med Chem 51:3388-3413.
23. 2 into human airways during acute antigen challenge. N Engl J Med 315:800-804.
24. 2. Nat Immunol 1:42-46.
25. Nagata K and Hirai H (2003) The second PGD2 receptor CRTH2: structure, properties, and functions in leukocytes. Prostaglandins Leukot Essent Fatty Acids 69:169-177. (Pubitemid 36976172)
26. 2α increases cyclooxygenase-1 action: a cross-talk between key enzymes in arachidonic acid pathway in prostate cancer cells. Biochim Biophys Acta 1801:731-737.
27. 2 on bronchial reactivity to sodium metabisulphite and methacholine in patients with asthma. Thorax 46:633-637.
28. Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF, Juniper EF, Ayres JG, Kemp L, Blyth A, et al. (2011) Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 364:1695-1707.
29. Schuligoi R, Sturm E, Luschnig P, Konya V, Philipose S, Sedej M, Waldhoer M, Peskar BA, and Heinemann A (2010) CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory disease. Pharmacology 85:372-382.
30. 2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 153:572-575.
31. 1α and β-thromboglobulin in antigen-induced asthma before and after indomethacin pretreatment. Br J Clin Pharmacol 19:459-470.
32. Siraganian RP (1974) An automated continuous-flow system for the extraction and fluorometric analysis of histamine. Anal Biochem 57:383-394.
33. Szczeklik A (1990) The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 3:588-593.
34. Szczeklik A, Mastalerz L, Nizankowska E, and Cmiel A (1996) Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am J Respir Crit Care Med 153:567-571. (Pubitemid 26051331)
35. 2 in allergic response and parturition. Nature 390:618-622.
36. van den Berge M, Luijk B, Bareille P, Dallow N, Postma DS, and Lammers JW (2010) Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma. Allergy 65:1531-1535.
37. Vancheri C, Mastruzzo C, Sortino MA, and Crimi N (2004) The lung as a privileged site for the beneficial actions of PGE2. Trends Immunol 25:40-46. (Pubitemid 38032806)